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Summary
Background.  —  Takotsubo  cardiomyopathy  (TTC)  is  a  rare  condition  characterized  by  a  sudden
temporary weakening  of  the  heart.  TTC  can  mimic  acute  myocardial  infarction  and  is  associated
with a  minimal  release  of  myocardial  biomarkers  in  the  absence  of  obstructive  coronary  artery
disease.
Aims. —  To  provide  an  extensive  description  of  patients  admitted  to  hospital  for  TTC  throughout
France and  to  study  the  management  and  outcomes  of  these  patients.
Methods.  —  In  14  non-academic  hospitals,  we  collected  clinical,  electrocardiographic,  biolog-
ical, psychological  and  therapeutic  data  in  patients  with  a  diagnosis  of  TTC  according  to  the
Mayo Clinic  criteria.
Results.  —  Of  117  patients,  91.5%  were  women,  mean  ±  SD  age  was  71.4  ±  12.1  years  and  the
prevalence  of  risk  factors  was  high  (hypertension:  57.9%,  dyslipidaemia:  33.0%,  diabetes:  11.5%,
obesity: 11.5%).  The  most  common  initial  symptoms  were  chest  pain  (80.5%)  and  dyspnoea
(24.1%). A  triggering  psychological  event  was  detected  in  64.3%  of  patients.  ST-segment  ele-
vation was  found  in  41.7%  of  patients  and  T-wave  inversion  in  71.6%.  Anterior  leads  were
most frequently  associated  with  ST-segment  elevation,  whereas  T-wave  inversion  was  more
commonly associated  with  lateral  leads,  and  Q-waves  with  septal  leads.  The  ratio  of  peak
B-type natriuretic  peptide  (BNP)  or  N-terminal  prohormone  BNP  (NT-proBNP)  level  to  peak  tro-
ponin level  was  1.01.  No  deaths  occurred  during  the  hospital  phase.  After  1  year  of  follow-up,
3 of  109  (2.8%)  patients  with  available  data  died,  including  one  cardiovascular  death.  Rehos-
pitalizations  occurred  in  17.4%  of  patients:  2.8%  due  to  acute  heart  failure  and  14.7%  due  to
non-cardiovascular  causes.  There  was  no  recurrence  of  TTC.
Conclusions.  —  This  observational  study  of  TTC  included  primarily  women  with  atherosclerotic
risk factors  and  mental  stress.  T-wave  inversion  was  more  common  than  ST-segment  elevation.
There were  few  adverse  cardiovascular  outcomes  in  these  patients  after  1-year  follow-up.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Le  syndrome  de  Takotsubo  est  une  affection  rare  caractérisée  par  un  affaiblisse-
ment temporaire  soudain  du  cœur.  Le  syndrome  de  Takotsubo  peut  simuler  un  infarctus  du
myocarde aigu  et  est  associé  à  une  élévation  minime  des  biomarqueurs  de  nécrose  myocardique
en l’absence  de  maladie  coronaire  obstructive.
Buts. —  Fournir  une  description  extensive  d’une  population  de  patients  admis  pour  un  syndrome
de Takotsubo  sur  le  territoire  franc¸ais  et  d’étudier  la  prise  en  charge  et  l’évolution  de  ces
patients.
Méthodes.  —  Nous  avons  rassemblé  les  données  cliniques,  électrocardiographiques,  biologiques,
psychologiques  et  thérapeutiques  chez  des  patients  admis  pour  un  syndrome  de  Takotsubo  sur
les critères  diagnostiques  de  la  Mayo  Clinic,  dans  14  hôpitaux  non  universitaires  de  France.
6  K.  Yayehd  et  al.
Résultats.  —  Cent  dix-sept  patients  ont  été  inclus.  Les  patients  étaient  en  majorité  des  femmes
(91,5 %)  d’âge  moyen  71,4  ±  12,1  ans,  présentant  fréquemment  des  facteurs  de  risque  cardio-
vasculaire  (hypertension  :  57,9  %,  dyslipidémie  :  33,0  %,  diabète  :  11,5  %,  obésité  :  11,5  %).
Les principaux  symptômes  à  l’admission  étaient  la  douleur  thoracique  (80,5  %)  et  la  dyspnée
(24,1 %).  Un  événement  psychologique  déclenchant  était  identiﬁé  chez  64,3  %  des  patients.
Le sus-décalage  du  segment  ST  était  retrouvé  chez  41,7  %  des  patients  et  une  inversion  de
l’onde T  dans  71,6  %  des  cas.  Les  dérivations  antérieures  étaient  les  plus  souvent  concernées
en cas  de  sus-décalage  du  ST,  les  dérivations  latérales  en  cas  d’inversion  de  l’onde  T  et  les
dérivations  septales  en  cas  d’onde  Q.  Le  rapport  BNP  ou  NT-proBNP/troponine  était  de  1,01.
Il n’y  avait  aucun  décès  hospitalier.  Après  un  an  de  suivi,  trois  patients  (2,8  %)  étaient  décédés
dont un  décès  de  cause  cardiovasculaire.  Des  réhospitalisations  ont  été  observées  chez  2,8  %  des
patients pour  insufﬁsance  cardiaque  aiguë,  et  pour  raisons  non  cardiovasculaires  chez  14,7  %
de ceux-ci.  Il  n’y  a  pas  eu  de  récidive  de  syndrome  de  Takotsubo.
Conclusions.  —  Cet  observatoire  du  syndrome  de  Takotsubo  a  inclus  des  femmes  ayant
de nombreux  facteurs  de  risque  cardiovasculaire  et  un  facteur  aigu  de  stress  mental.
L’électrocardiogramme  montrait  dans  moins  de  la  moitié  des  cas  un  sus-décalage  ST  et  plus
fréquemment  une  inversion  de  l’onde  T.  Il  y  avait  peu  de  complications  cardiovasculaires  après
un suivi  d’un  an.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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akotsubo  cardiomyopathy  (TTC)  is  a  cardiac  syndrome
haracterized  by  transient  left  ventricular  dysfunction,
lectrocardiographic  changes  that  can  mimic  acute  myocar-
ial  infarction,  and  a  minimal  release  of  myocardial
iomarkers  in  the  absence  of  obstructive  coronary  artery
isease  [1—4].  Observational  data  from  cohorts  of  patients
resenting  with  acute  TTC  provide  the  opportunity  to
mprove  the  knowledge  of  this  syndrome.  While  data  from
ome  observational  studies  have  been  particularly  helpful
5—7],  others  suffer  from  a  relative  lack  of  representative-
ess  [6]  or  are  highly  representative  but  did  not  collect
xtensive  clinical  data  [5].  Mansencal  et  al.  provided  epi-
emiological  data  on  TTC  in  the  Paris  area  [7]; however,
here  are  no  nationwide  data  on  the  management  of  this
isease.
The  Observational  French  SyndromEs  of  TakoTsubo
OFSETT)  was  designed  to  collect  extensive  nationwide  data
rom  patients  hospitalized  for  TTC  with  a  follow-up  of  1
ear.  A  distinctive  feature  of  OFSETT  is  the  comprehensive
ata  collected  in  terms  of  clinical,  electrocardiographic,
iological  and  psychological  aspects,  and  the  treatment  of
hese  patients.  The  aims  of  OFSETT  were  to  provide  detailed
escription  of  the  population  of  patients  admitted  for  TTC
hroughout  France.
ethods
tudy design
FSETT  was  a  multicentre  observational  study  of  TTC  diag-
osed  in  French  non-academic  hospitals  (Appendix  A).  The
tudy  prospectively  included  consecutive  patients  with  TTC
rom  December  2010  to  December  2011.  To  increase  the
umber  of  patients  included,  the  study  also  collected  data
etrospectively  from  the  hospital  records  of  patients  admit-
ed  with  this  syndrome  from  November  2005  to  November
010  in  the  same  centres.
D
A
eThe  cardiologists  who  participated  in  the  study  were  not
upposed  to  modify  their  therapeutic  approach  for  these
atients  in  any  way.  Patients  provided  written  informed
onsent  to  participate.  The  study  was  conducted  in  accor-
ance  with  good  clinical  practice,  French  law  and  the  French
ata  protection  law.  The  data  recorded  and  the  way  they
ere  handled  and  stored  were  reviewed  and  approved  by
he  Comité  consultatif  sur  le  traitement  de  l’information
n  matière  de  recherche  dans  le  domaine  de  la  santé  (No.
CTIRS:  10.067)  and  the  Commission  nationale  informatique
t  liberté  (No.  CNIL:  910131).
atients and centres
ligible  patients  were  ≥18  years  of  age  and  met  the  Mayo
linic  diagnostic  criteria  for  TTC  [8],  namely:  transient
ypokinesis,  akinesis  or  dyskinesis  of  the  left  ventricular
id-segments  with  or  without  apical  involvement;  regional
all  motion  abnormalities  extend  beyond  a  single  epicar-
ial  vascular  distribution;  a  stressful  trigger  is  often,  but
ot  always,  present;  the  absence  of  obstructive  coronary
isease  or  angiographic  evidence  of  acute  plaque  rupture;
ppearance  of  new  electrocardiographic  (ECG)  abnormali-
ies  (ST-segment  elevation  and/or  T-wave  inversion)  or  a
odest  elevation  in  cardiac  troponin;  and  the  absence  of
heochromocytoma  or  myocarditis.  No  exclusion  criteria
ere  applied.  All  patients  underwent  coronary  angiography
n  admission.
Centres  selected  to  participate  were  required  to  have
 cardiac  intensive  care  unit  and  a  catheterization  labo-
atory  available  24/7  and  to  perform  >1000  percutaneous
oronary  interventions  per  year.  Of  83  non-academic  hos-
itals  with  interventional  cardiology  facilities  in  France,  30
ulﬁlled  these  criteria  and  14  agreed  to  participate.ata collection
 computerized  case  record  form  was  completed  for
ach  eligible  patient,  based  on  hospital  records  and
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additional  speciﬁc  questionnaires.  The  following  data  were
collected:  medical  history  and  presenting  characteristics
(clinical  characteristics  including  psychological  assessment,
electrocardiographic,  echocardiographic  and  angiographic
characteristics);  cardiac  biomarkers  (troponin  and  B-type
natriuretic  peptide  [BNP]  or  N-terminal  prohormone  BNP
[NT-proBNP]);  and  treatment  at  admission  and  at  discharge.
Patients  were  followed  up  for  1  year.  The  outcomes  were
in-hospital  complications,  all-cause  death,  cardiac  rehospi-
talization  (including  recurrence  of  TTC  and  heart  failure)
and  non-cardiac  rehospitalization  at  1  year.
Deﬁnitions
Peak  cardiac  troponin  and  peak  BNP  or  NT-proBNP  levels
are  expressed  as  multiples  of  the  upper  limit  of  normal
(ULN)  —  deﬁned  as  the  99th  percentile  —  in  each  biolog-
ical  laboratory  because  the  ULN  of  these  tests  can  differ
by  laboratory  and  type  of  reagent  used.  The  ratio  of  peak
BNP  or  NT-proBNP  increase  (multiple  of  the  ULN)  to  peak
troponin  increase  (multiple  of  the  ULN)  was  calculated  for
each  patient  with  available  data.
The  triggering  stressor  event  was  assessed  in  each
patient.  Physical  stress  was  deﬁned  as  the  force  applied  to  a
given  area  of  biological  tissue,  and  included  surgical  proce-
dures  such  as  cholecystectomy,  colonoscopy,  difﬁcult  urinary
catheterization,  pacemaker  implantation  and  electrical  car-
dioversion  [9,10].  Mental  stress  (emotionally  induced  stress)
included  the  death,  severe  illness  or  injury  of  a  loved  one;
the  receipt  of  bad  news;  a  severe  argument;  an  assault;
public  speaking;  ﬁnancial  loss;  a  car  accident;  and  natural
disasters  [9,11].
Statistical analysis
Categorical  variables  are  expressed  as  counts  and  percent-
ages  and  comparisons  were  made  using  the  Chi-square  test
or  Fisher’s  exact  test.  Continuous  variables  are  expressed
as  means  and  standard  deviations  (SDs)  or  medians  and
interquartile  ranges  (IQRs)  and  comparisons  were  made
with  Student’s  t  test  or  the  Mann-Whitney  U  test.  For  all
tests,  statistical  signiﬁcance  was  set  at  P  <  0.05.  The  data
were  analysed  using  Stata  SE  10  (Stata  Statistical  Software:
Release  10  [2007];  StataCorp  LP,  College  Station,  Texas,
USA).
Results
The  study  population  comprised  117  patients,  56  of  whom
were  enrolled  prospectively  and  61  retrospectively.  Most  of
the  patients  were  women  (91.5%),  the  mean  ±  SD  age  was
71.4  ±  12.1  years  and  the  prevalence  of  risk  factors  was
high  (Table  1).  The  only  signiﬁcant  difference  between  the
retrospective  and  prospective  groups  was  more  frequent
prevalence  of  diabetes  mellitus  in  the  prospective  group
(P  =  0.03).  The  most  common  initial  symptoms  were  chest
pain  (80.5%)  and  dyspnoea  (24.1%).  A  triggering  event  was
detected  in  64.3%  of  patients.  Among  patients  for  whom  a
triggering  event  was  detected,  mental  stress  was  found  in
70.4%  and  physical  stress  in  26.1%.
D
t
rigure 1. Precordium electrocardiographic lead positions for: (A)
T-segment elevation, (B) T-wave inversion and (C) Q-waves.
ST-segment  elevation  was  found  in  45/117  (41.7%)
atients  and  T-wave  inversion  in  78/117  (71.6%)  patients.
-wave  was  present  in  30/117  (29.1%)  patients.  The  pre-
ordium  localizations  by  lead  number  are  shown  in  Fig.  1.
nterior  leads  were  most  frequently  associated  with  ST-
egment  elevation,  whereas  T-wave  inversion  was  more
ommonly  associated  with  lateral  leads  and  Q-waves  with
eptal  leads.
ardiac biomarkersata  on  cardiac  biomarkers  are  shown  in  Table  2. Among
he  35  patients  who  had  sufﬁcient  data  to  calculate  the
atio  BNP  (or  NT-proBNP)/troponin,  the  median  increase  of
8  K.  Yayehd  et  al.
Table  1  Baseline  characteristics.
Characteristics  All  OFSETT  (n  =  117)  Prospective  group  (n  =  56)  Retrospective  group  (n  =  61)
Women  107/117  (91.5)  51/56  (91.1)  56/61  (91.8)
Age  (years)  71.4  ±  12.1  70.5  ±  12.5  72.3  ±  11.8
Admission  mode
Mobile  intensive  care  unit  56/114  (49.1)  31/54  (57.4)  25/60  (41.7)
Emergency  department  34/114  (29.8)  14/54  (25.9)  20/60  (33.3)
Cardiovascular  risk  factors
Hypertension  66/114  (57.9) 29/55  (52.7) 37/59  (62.7)
Diabetes  mellitus 13/113  (11.5) 10/55  (18.2) 3/58  (5.2)a
Active  smokers 6/111  (5.4) 5/54  (9.3) 1/59  (1.7)
Obesity  (BMI  ≥30  kg/m2)  11/96  (11.5)  7/47  (14.9)  4/49  (8.2)
Dyslipidaemia  37/112  (33.0)  20/54  (37.0)  17/58  (29.3)
Psychiatric  history  11/110  (10.0)  6/54  (11.1)  5/56  (8.9)
Medical  history
Previous  stroke/TIA 7/113  (6.2) 4/54  (7.4) 3/59  (5.1)
Previous  coronary  heart  disease 8/113  (7.1) 6/54  (11.1)  2/59  (3.4)
Peripheral  artery  disease 7/111  (6.3) 1/53  (1.9) 6/58  (10.3)
COPD  6/111  (5.4) 3/53  (5.7) 3/59  (5.1)
Chronic  kidney  disease 1/91  (1.1) 0/32  (0.0) 1/59  (1.7)
Symptoms  at  admission
Chest  pain  91/113  (80.5)  41/54  (75.9)  50/59  (84.7)
Dyspnoea  27/112  (24.1)  12/54  (22.2)  15/58  (25.9)
Syncope  7/114  (6.1)  4/54  (7.4)  3/60  (5.0)
Clinical  examination
Heart  rate  (beats/min)  82.5  ±  16.8  84.1  ±  14.4  80.9  ±  18.8
Systolic  blood  pressure  (mmHg)  129.3  ±  23.2  129.3  ±  23.4  129.3  ±  23.2
Acute  heart  failure  7/113  (6.2)  2/53  (3.8)  5/60  (8.3)
Cardiogenic  shock  4/112  (3.6)  2/52  (3.8)  2/60  (3.3)
Psychological  events
Identiﬁable  74/115  (64.3)  41/56  (73.2)  33/59  (55.9)
Mental  stressb 50/71  (70.4)  25/38  (65.8)  25/33  (75.8)
Physical  stressb 18/69  (26.1)  10/37  (27.0)  8/32  (25.0)
Data are n/N (%) or mean ± standard deviation. BMI: body mass index; COPD: chronic obstructive pulmonary disease; MICU: mobile
intensive care unit; TIA: transient ischaemic attack.
a P = 0.03 (all other between-group P-values were non-signiﬁcant).
b Among subjects with an identiﬁable psychological event.
Table  2  Cardiac  biomarkers.
Characteristics  All  OFSETT  Prospective  group  Retrospective  groupa
Peak  troponin  level  (pg/mL;  n  =  117)  4.9  (0.9—215)  4.4  (0.9—113)  5.2  (0.9—270)
Peak  BNP  level  (pg/mL;  n  =  23)  527  (285—1005)  482  (285—1005)  536  (238—1088)
Peak  NT-proBNP  level  (pg/mL;  n  =  27)  4735  (2329—12,156)  6292  (2351—11,684)  4363  (2329—12,300)
Peak  troponin  increaseb (n  =  108)  9.0  (2.7—22.4)  10.4  (3.0—35.7)  6.2  (2.4—18.2)
Peak  BNP  or  NT-proBNP  increaseb (n  =  37)  7.6  (3.6—14.5)  8.0  (3.5—23.5)  5.5  (3.4—11.7)
Peak  BNP  (or  NT-proBNP)  increase/peak
troponin  increaseb (n  =  35)
1.01  (0.15—7.6)  1.03  (0.15—5.41)  0.92  (0.17—7.6)
Data are median (interquartile range).
a Between-group (prospective vs. retrospective) P-values (Mann-Whitney U test) were non-signiﬁcant.
b Multiple of the upper limit of normal (99th percentile) in each biological laboratory.
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Table  3  Echocardiographic,  angiographic  and  ventriculographic  characteristics.
Characteristics  All  OFSETT
(n =  117)
Prospective
group  (n  =  56)
Retrospective
group (n  =  61)a
Echocardiographic  characteristics
Typical  pattern  of  TTCb 79  (67.5)  37  (66.1)  42  (68.9)
Atypical  pattern  of  TTCc 37  (31.6)  18  (32.1)  19  (31.1)
Inverted  TTCd 1  (0.9)  1  (1.8)  0  (0)
LVEFb (%)  41.7  ±  10.1  41.2  ±  10.8  42.2  ±  9.6
Angiographic  and  ventriculographic  characteristics
Normal  coronary  angiography  92  (76.9)  41  (71.4)  51  (82.0)
Non-signiﬁcant  abnormalities 25  (21.4) 15  (26.8) 10  (16.4)
LVEFc (%) 45.7  ±  12.2 45.1  ±  13.0 46.2  ±  11.8
Data are n/N (%) or mean ± standard deviation. LVEF: left ventricular ejection fraction.
a Between-group (prospective vs. retrospective) P-values were non-signiﬁcant.
b Apical ballooning of the left ventricle.
c Regional wall motion abnormalities involved apex and/or mid-ventricular segments.
d Basal ballooning of the left ventricle.
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tthe  peak  troponin  level  was  9.0  (2.7—22.4)  for  BNP  and  7.6
(3.6—14.5)  for  NT-proBNP  levels.  The  median  of  the  ratio  of
peak  BNP  (or  NT-proBNP)  to  peak  troponin  was  close  to  1.
Echocardiographic, angiographic and
ventriculographic characteristics
The  typical  pattern  of  TTC  (apical  ballooning)  was  observed
in  67.5%  of  patients  at  echocardiography  (Table  3).  All
117  patients  underwent  coronary  angiography  and  89/117
(76.1%)  had  supplementary  ventriculography.  Coronary
angiography  results  were  normal  in  76.9%  of  patients,  while
21.4%  had  non-signiﬁcant  abnormalities  and  angiographi-
cally  stable  coronary  stenosis.  One  patient  had  signiﬁcant
stenosis  of  a  ﬁrst  diagonal  and  one  patient  had  signiﬁ-
cant  stenosis  of  an  artery  bisector  of  small  calibre,  but
in  these  two  cases,  the  regional  wall  motion  abnormality
did  not  correspond  with  the  coronary  artery  distribu-
tion.  Cardiac  assessment  with  other  imaging  techniques
was  also  undertaken  in  some  patients:  cardiac  magnetic
resonance  imaging  (MRI;  n  =  26),  myocardial  scintigraphy
(n  =  5)  and  computed  tomography  coronary  angiography
(n  =  1).  These  imaging  techniques  conﬁrmed  the  diagnosis
of  TTC.
Medical treatments
At  admission,  one  patient  had  received  prehospital  throm-
bolytic  therapy  administered  in  a  mobile  intensive  care
unit.  No  patients  received  thrombolysis  while  in  hos-
pital.  Aspirin  (93.3%),  clopidogrel  (83.0%)  and  statins
(62.4%)  were  started  at  admission  to  hospital  (Table  4).
Aspirin  and  clopidogrel  were  maintained  at  discharge
in  60.6  and  27.9%  of  patients,  respectively.  Psycholog-
ical  management  was  provided  in  88  patients,  most
often  by  cardiologists  (52  patients)  and  nurses  (23
patients;  Table  4).  The  intervention  of  a  psychiatrist
was  justiﬁed  in  12  patients  and  a  psychologist  in  one
patient.
a
p
q
mlinical outcome
o  deaths  occurred  during  hospitalization  and  there  were
o  transfers  to  the  psychiatric  department.  In-hospital
vents  were  mainly  haemodynamic  complications  and  car-
iac  rhythm  disorders  (7.2%),  essentially  supra-ventricular
rrhythmia.
One-year  follow-up  data  were  available  in  109/117
atients  (93.2%).  Three  patients  (2.8%)  died,  all  in  the
etrospective  group,  one  from  a  lung  adenocarcinoma  at
 months,  one  from  a  pulmonary  infection  at  51  days
nd  one  from  sudden  death  at  3  months.  Cardiac  rehos-
italizations  (all  for  heart  failure)  occurred  in  2.8%  of
atients  (1/54  [1.9%]  in  the  retrospective  group  vs.  2/55
3.6%]  in  the  prospective  group,  P  =  NS).  Sixteen  patients
14.7%)  were  rehospitalized  for  a  non-cardiac  reason  (7/54
13.0%]  in  the  retrospective  group  vs.  9/55  [16.4%]  in  the
rospective  group,  P  =  NS).  There  was  no  recurrence  of
TC.
iscussion
n  OFSETT,  the  population  of  patients  with  TTC  comprised
ainly  postmenopausal  women  with  atherosclerotic  risk
actors  who  presented  with  chest  pain  and/or  dyspnoea
t  admission,  as  has  been  reported  in  other  observational
tudies  [5,12].  Less  than  50%  of  patients  had  ST-segment
levation.  The  clinical  presentation  of  TTC  was  similar
o  that  of  acute  coronary  syndromes  (ACS)  [4]. However,
he  OFSETT  population  included  fewer  smokers  (5.4%)  and
atients  with  diabetes  mellitus  (11.5%)  than  did  patients
ith  ACS  in  the  FAST-MI  study  (34  and  21%,  respectively)
13].
Patients  in  OFSETT  presented  with  more  mental  stress
han  physical  stress,  contrary  to  the  ﬁnding  of  Namgung  in study  of  Korean  patients  [14].  ST-segment  elevation  was
resent  in  less  than  half  of  our  patients  (and  was  more  fre-
uently  found  in  anterior  leads);  T-wave  inversion  was  the
ost  common  ECG  abnormality  (and  was  more  frequently
10  K.  Yayehd  et  al.
Table  4  Medical  treatment.
Characteristics  All  OFSETT
(n =  117)
Prospective
group  (n  =  56)
Retrospective
group  (n  =  61)
Treatment  started  at  admission
ACE  inhibitors/ARB  78/104  (75.0)  35/49  (71.4)  43/55  (78.2)
Aspirin  97/103  (93.3)  48/49  (98.0)  49/54  (89.1)
Beta-blocker  78/103  (75.7)  40/50  (80.0)  38/53  (71.7)
Clopidogrel  88/106  (83.0) 44/50  (88.0)  44/56  (78.6)
Glyceryl  trinitrate 13/101  (12.9) 6/50  (12.0) 7/51  (13.7)
LMWH/fondaparinux  79/108  (76.7) 37/48  (77.1) 42/55  (76.4)
Statin  63/101  (62.4) 30/48  (62.5) 33/53  (62.3)
Unfractionated  heparin  26/100  (26.0)  7/46  (15.2)  19/54  (35.2)a
Treatment  at  discharge
ACE  inhibitors/ARB  84/105  (80.0)  40/49  (81.6)  44/56  (78.6)
Aspirin  66/109  (60.6)  31/50  (62.0)  35/59  (59.3)
Beta-blocker  80/108  (74.1) 43/50  (86.0) 37/58  (63.8)b
Clopidogrel  29/104  (27.9) 15/47  (32.9) 14/57  (24.6)
Glyceryl  trinitrate 1/103  (1.0) 1/47  (2.1) 0/56  (0)
Statin  49/102  (48.0) 24/47  (51.1) 25/55  (45.5)
Psychological  management
By  cardiologist  52/102  (51.0)  24/49  (49.0)  28/53  (52.8)
By  nurse  23/90  (25.6)  12/44  (27.3)  11/46  (23.9)
By  psychiatrist  12/99  (12.1)  6/48  (12.5)  6/51  (11.8)
By  psychologist  1/97  (1.0)  0/46  (0)  1/51  (2.0)
Data are n/N (%). ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; LMWH: low-molecular-weight heparin.
a P = 0.02 (prospective vs. retrospective).
b P = 0.008 (prospective vs. retrospective).
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tound  in  lateral  leads)  and  Q-waves  were  the  least  com-
on  ECG  change  (and  the  more  frequently  found  in  septal
eads)  —  in  contrast  to  that  previously  described  in  the  lit-
rature.  Two  systematic  reviews  —  by  Pilgrim  and  Wyss  [15]
nd  Gianni  et  al.  [1]  —  showed  that  ST-segment  elevation
as  the  most  common  ECG  change  in  TTC  (81.6  and  71.0%,
espectively)  followed  by  T-wave  inversion  (61.3  and  64.3%,
espectively)  and  pathological  Q-waves  (31.1  and  31.8%,
espectively).  ST-segment  elevation  was  also  the  common
CG  ﬁnding  in  several  other  studies  [5,7,12,16].
In  the  present  study,  peak  cardiac  troponin  levels  were
odest  compared  to  that  observed  in  acute  myocar-
ial  infarction  [4,17—19];  and  the  ratio  of  BNP  (or
T-proBNP)  to  troponin  was  1.01.  This  ratio  of  around
 is  uncommon  in  acute  myocardial  infarction,  where
roponin  elevation  is  higher  than  BNP  elevation  [17,18].
n  a  recent  prospective  multicentre  report,  which  com-
ared  62  patients  with  TTC  to  90  with  an  ACS,  Doyen
t  al.  [20]  observed  that  BNP  levels  were  higher  in
atients  with  TTC  but  also  that  troponin  levels  were  lower
han  those  in  patients  with  ST-segment  elevation  myocar-
ial  infarction,  and  similar  to  those  in  non-ST-segment
levation  myocardial  infarction.  Therefore,  the  ratio  of
NP  to  troponin  levels  may  help  to  differentiate  TTC
rom  ST-segment  elevation  myocardial  infarction  [17,18].
lthough  many  observational  studies  have  reported  a  sig-
iﬁcant  rise  in  troponin  in  patients  with  TTC,  they  did  not
easure  BNP  concentrations  in  their  patients  [5,12,21].
ome  authors  observed  that  BNP  and  NT-proBNP  are  sub-
tantially  elevated  and  signiﬁcantly  increased  during  the
o
o
o
trst  24  hours  after  the  onset  of  TTC,  with  slow  and
ncomplete  resolution  during  the  3  months  thereafter;
nd  the  peak  NT-proBNP  concentration  correlated  with
he  severity  of  regional  wall  motion  abnormality  or  sys-
olic  dysfunction  assessed  by  echocardiography  [22].  Ribeiro
t  al.  suggested  that  BNP  or  NT-proBNP  may  also  predict
omplications  during  hospitalization  [23].
Only  one  patient  received  prehospital  ﬁbrinolysis,  indi-
ating  the  merit  of  primary  coronary  angiography  to  avoid
nappropriate  ﬁbrinolysis  in  these  patients.  The  French
mergency  Medical  System  has  medical  intensive  care  units
hat  allow  most  patients  with  an  ACS  to  be  admitted
uickly  to  a  catheterization  laboratory  [13,24,25].  At  admis-
ion,  the  treatment  of  TTC  is  similar  to  that  of  ACS,
ncluding  administration  of  antiplatelet  agents  and  low-
olecular-weight  heparin  or  fondaparinux  in  a  cardiac
ntensive  care  unit.  Once  a diagnosis  of  TTC  has  been
ade,  treatment  usually  involves  standard  heart  failure
herapy,  such  as  angiotensin-converting  enzyme  inhibitors
nd  beta-blockers  [26], and  suitable  psychological  care  is
iven  at  discharge.  In  the  present  study,  antiplatelet  agents
ere  maintained  at  discharge  in  many  patients  due  to
he  lack  of  diagnosis  conﬁrmation;  however,  at  subsequent
ollow-up  with  cardiologists  these  treatments  were  discon-
inued.
Few  complications  and  no  in-hospital  deaths  were
bserved  in  the  present  study,  and  there  was  no  recurrence
f  TTC.  Previous  studies  have  also  reported  a  good  prognosis
f  TTC,  with  in-hospital  complication  rates  ranging  from  1.2
o  4.2%  [1,27].  Recurrence  rates  range  from  0  to  15%  [6,28].
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Rehospitalization  for  non-cardiovascular  causes  is  common
in  this  older  population.
This  study  was  conducted  in  non-academic  hospitals
because,  nationwide,  they  take  care  of  61%  of  patients  with
an  ACS  and  represent  32%  of  interventional  cardiology  activ-
ity  [29].
Limitations
The  need  for  a  sufﬁcient  number  of  patients  with  TTC  to
enable  statistical  analysis  in  a  short  time  required  us  to  dis-
tinguish  two  phases  (prospective  and  retrospective),  with
the  associated  risks  of  different  data  collection  and  treat-
ment.  Comparison  of  the  two  phases  has,  however,  revealed
no  statistically  signiﬁcant  differences  to  prevent  the  merg-
ing  of  the  two  cohorts,  except  for  diabetes  mellitus.  The
completeness  of  data  collection  also  allowed  a  satisfac-
tory  analysis.  Second,  cardiac  MRI  was  performed  in  only
22.2%  of  patients  in  OFSETT  for  logistical  reasons.  Cardiac
MRI  offers  a  signiﬁcant  advance,  allowing  the  elimination
of  necrosis,  conﬁrming  the  disappearance  of  apical  bal-
looning  and  the  restoration  of  a  normal  left  ventricular
ejection  fraction,  and  it  would  be  regrettable  not  to  gather
such  data  in  this  ﬁeld  [30].  The  usefulness  of  MRI  is  estab-
lished  in  the  assessment  of  left  ventricular  function  and  the
detection  of  apical  thrombus  or  right  ventricular  involve-
ment  [31,32].  Cardiac  MRI  can  distinguish  TTC  from  acute
myocardial  infarction  [33]  and  its  systematic  use  should  be
proposed.  Third,  as  this  was  an  observational  study  some  of
the  data  are  incomplete.  Less  than  50%  patients  had  BNP
or  NT-proBNP  data.  The  measurement  of  BNP  should  be  sys-
tematic  since  cardiac  biomarker  levels  appear  helpful  for
the  diagnosis.
Conclusions
This  observational  study  of  TTC  included  primarily  elderly
women  with  high  prevalence  of  atherosclerotic  risk  factors
and  mental  stress  who  presented  with  chest  pain  and/or
dyspnoea.  Less  than  half  of  the  patients  had  ST-segment
elevation,  but  nearly  three-quarters  had  T-wave  inversion.
There  were  few  adverse  cardiovascular  outcomes  in  these
patients  after  1-year  follow-up.
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ppendix A. OFSETT participating sites,
nvestigators and number of patients
nrolled
ite  Investigator  Number  of
patients
enrolled
entre  hospitalier
d’Haguenau
(Haguenau)
Dr  Hanssen 27
entre  hospitalier
Saint-Joseph  —
Saint-Luc  (Lyon)
Dr Aupetit  23
olyclinique  les  Fleurs
(Olliuoles)
Dr  Commeau  14
entre  hospitalier
Bretagne-Atlantique
(Vannes)
Dr  Filippi  11
entre  hospitalier
d’Annecy  (Annecy)
Dr Belle  11
entre  hospitalier  de
Versailles  —  hôpital
André-Mignot  (Le
Chesnay)
Dr  Georges  10
es  hôpitaux  de
Chartres  (Chartres)
Dr Albert  4
entre  hospitalier  de
Compiègne
(Compiègne)
Dr  Meimoun  4
entre  hospitalier  de
Vichy  (Vichy)
Dr  Marcaggi  4
entre  hospitalier
Bretagne-Sud
(Lorient)
Dr  Baleynaud 3
roupe  hospitalier
intercommunal  Le
Raincy-Montfermeil
(Montfermeil)
Dr Cattan  2
nstitut  mutualiste
Montsouris  (Paris)
Dr Dibie  2
entre  hospitalier  du
Pays  d’Aix
(Aix-En-Provence)
Dr  Barnay  1
entre  hospitalier  du
Mans  (Le  Mans)
Dr Legrand  1
otal  117
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